May, 2025

U.S.A.
News / Therapeutic Area News
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months,...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO, May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...
Read More

Feb, 2025

U.S.A.
News / Therapeutic Area News
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment...
Read More

Jan, 2025

U.S.A.
News / Therapeutic Area News
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer
- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care...
Read More

Dec, 2024

U.S.A.
News / Therapeutic Area News
Astellas Pharma US, Inc. Issues Voluntary Nationwide Recall of One Lot of PROGRAF® 0.5mg (tacrolimus) and One Lot of ASTAGRAF XL® 0.5mg (tacrolimus extended-release capsules) because bottles shipped to U.S. may contain empty capsules
FOR IMMEDIATE RELEASE – NORTHBROOK, IL, Dec. 23, 2024 – Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") is voluntarily recalling one lot of PROGRAF® 0.5mg...
Read More